Insider Buying Richard Christopher Acquires 50,000 Shares of Lexaria Bioscience Corp
| LEXX Stock | USD 2.16 0.05 2.26% |
Slightly above 62% of Lexaria Bioscience's investor base is looking to short. The analysis of the overall investor sentiment regarding Lexaria Bioscience Corp suggests that many traders are alarmed. Lexaria Bioscience's investing sentiment can be driven by a variety of factors including economic data, Lexaria Bioscience's earnings reports, geopolitical events, and overall market trends.
Lexaria |
On December 3, 2024, Richard Christopher, the Chief Executive Officer of Lexaria Bioscience Corp, purchased 50,000 shares of the company, according to a SEC Fil
Read at gurufocus.com
 |
Lexaria Bioscience Fundamental Analysis
We analyze Lexaria Bioscience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lexaria Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lexaria Bioscience based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Debt To Equity
Debt To Equity Comparative Analysis
Lexaria Bioscience is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Lexaria Bioscience Corp Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lexaria Bioscience stock to make a market-neutral strategy. Peer analysis of Lexaria Bioscience could also be used in its relative valuation, which is a method of valuing Lexaria Bioscience by comparing valuation metrics with similar companies.
Peers
Lexaria Bioscience Related Equities
| ZVSA | ZyVersa Therapeutics | 24.58 | ||||
| CNSP | Cns Pharmaceuticals | 9.09 | ||||
| BDRX | Biodexa Pharmaceticals | 5.85 | ||||
| SONN | Sonnet Biotherapeutics | 1.94 | ||||
| ZURA | Zura Bio | 0.46 | ||||
| ICU | LMF Acquisition | 2.93 | ||||
| RNAZ | Transcode Therapeutics | 4.37 | ||||
| PHIO | Phio Pharmaceuticals | 6.63 | ||||
| IMMX | Immix Biopharma | 6.67 | ||||
| REVB | Revelation Biosciences | 8.62 |
Additional Tools for Lexaria Stock Analysis
When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.